Semaglutide injection (Novotai) is a new long-acting glucagon-like peptide-1 (GLP-1) analogue from Novo Nordisk [1]
, has 94% sequence homology with human GLP-1. Mainly used for blood sugar control in adults with type 2 diabetes: On the basis of diet control and exercise, adults with type 2 diabetes who still have poor blood sugar control after receiving metformin and/or sulfonylureas. It is suitable for reducing the risk of major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes and cardiovascular disease.
Dosage
The starting dose of semaglutide is 0.25 mg once weekly. After 4 weeks, it should be increased to 0.5mg once a week. After at least 4 weeks of treatment with 0.5 mg once weekly, the dose may be increased to 1 mg once weekly to further improve glycemic control. This product 0.25mg is not a maintenance dose. Doses above 1 mg per week are not recommended